ALK-Abelló A/S (LON:0OIR)

Market Cap	5.83B
Revenue (ttm)	710.34M
Net Income (ttm)	128.67M
Shares Out	n/a
EPS (ttm)	0.58
PE Ratio	45.30
Forward PE	36.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,939
Average Volume	25,440
Open	225.00
Previous Close	224.40
Day's Range	221.20 - 225.00
52-Week Range	131.30 - 237.60
Beta	0.70
RSI	47.58
Earnings Date	Feb 3, 2026

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1923
• Employees: 2,753
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0OIR

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial numbers in DKK